Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL461303 | 0.78 | L3MBTL1 (0.30) | — | |
| SCHEMBL134231 | 0.76 | — | — | |
| SCHEMBL77719 | 0.71 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL21313113 | 0.69 | — | — | |
| SCHEMBL9655855 | 0.65 | TSHR (0.31) | — | |
| SCHEMBL12404534 | 0.65 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL9657194 | 0.65 | — | — | |
| 1,4-Butanediol SCHEMBL867061 | 0.63 | L3MBTL1 (0.35) | ALDH1A1 | |
| SCHEMBL1453490 | 0.63 | — | — | |
| SCHEMBL4185614 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297078-B1 | ALLYL AND PROPARGYL ETHERS | DSM IP ASSETS BV (NL) | 2015-08-19 | — | — | EP | claimed |
| US-8563780-B2 | Allyl and propargyl ethers | DSM IP ASSETS B.V. (NL) | 2013-10-22 | — | — | US | claimed |
| US-20120029240-A1 | ALLYL AND PROPARGYL ETHERS | DSM IP ASSETS B.V. (NL) | 2012-02-02 | — | — | US | claimed |
| EP-2297078-A1 | ALLYL AND PROPARGYL ETHERS | DSM IP Assets B.V. (NL) | 2011-03-23 | — | — | EP | claimed |
| WO-2009138389-A1 | ALLYL AND PROPARGYL ETHERS | DSM IP ASSETS B.V. (NL) | 2009-11-19 | — | — | WO | claimed |
| EP-2297078-B1 | ALLYL AND PROPARGYL ETHERS | DSM IP ASSETS BV (NL) | 2015-08-19 | — | — | EP | disclosed |
| US-8563780-B2 | Allyl and propargyl ethers | DSM IP ASSETS B.V. (NL) | 2013-10-22 | — | — | US | disclosed |
| US-8563780-B2 | Allyl and propargyl ethers | DSM IP ASSETS B.V. (NL) | 2013-10-22 | — | — | US | disclosed |
| US-20120029240-A1 | ALLYL AND PROPARGYL ETHERS | DSM IP ASSETS B.V. (NL) | 2012-02-02 | — | — | US | disclosed |
| US-20120029240-A1 | ALLYL AND PROPARGYL ETHERS | DSM IP ASSETS B.V. (NL) | 2012-02-02 | — | — | US | disclosed |
| EP-2297078-A1 | ALLYL AND PROPARGYL ETHERS | DSM IP Assets B.V. (NL) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009138389-A1 | ALLYL AND PROPARGYL ETHERS | DSM IP ASSETS B.V. (NL) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029240-A1 | ALLYL AND PROPARGYL ETHERS | EBP, ECH1, AKR1C3 | ALDH1A1 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.